44 reports

  • Birch Pollen Allergy - Drug Profiles
  • VACCINE FOR BIRCH POLLEN ALLERGY - DRUG PROFILE

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Asthma
  • Immunotherapy
  • Product Initiative
  • Anergis SA
  • Birch Pollen Allergy - Drug Profiles
  • VACCINES FOR BIRCH POLLEN ALLERGY - DRUG PROFILE

The drug candidate acts by targeting pollen allergen Bet v ##.

  • Allergy
  • Allergy Immunotherapy
  • Asthma
  • Product Initiative
  • Anergis SA
  • Cat Allergy - Drug Profiles
  • Sementis Ltd

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Asthma
  • United States
  • World
  • Product Initiative
  • DRUG FOR PEANUT ALLERGY - DRUG PROFILE
  • VACCINE FOR PEANUT ALLERGY - DRUG PROFILE

PATIENTS WERE RANDOMIZED IN A ##:## FASHION TO ACTIVE DRUG VERSUS PLACEBO.

  • Allergy
  • Allergy Immunotherapy
  • Asthma
  • Immunotherapy
  • Therapy
  • VACCINE FOR PEANUT ALLERGY - DRUG PROFILE
  • ALLERGEN FOR PEANUT ALLERGY - DRUG PROFILE

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Allergy Immunotherapy
  • Asthma
  • Immunotherapy
  • Therapy
  • SCOPE OF THE STUDY
  • ALLERGY TREATMENT MARKET

The 2018 ACAAI data also states that, across the world, adverse drug reactions may affect up to one-tenth of the world' s population and affect up to one-fifth of all hospitalized patients.

  • Allergy
  • Asthma
  • Market Segment
  • Market Size
  • F. Hoffmann-La Roche Ltd.
  • Grass Pollen Allergy - Drug Profiles
  • Vaccine for Grass Pollen Allergy - Drug Profile

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Asthma
  • Immunotherapy
  • United States
  • Product Initiative
  • Ragweed Pollen Allergy - Drug Profiles
  • Allergan for Ragweed Pollen Allergy - Drug Profile

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Asthma
  • Chronic Disease
  • Biomay AG
  • Ragweed Pollen Allergy - Drug Profiles
  • Allergan for Ragweed Pollen Allergy - Drug Profile

Food and Drug Administration (FDA) has approved RAGWITEK™ (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use (## Amb a ##-U).

  • Allergy
  • Allergy Immunotherapy
  • Asthma
  • Chronic Disease
  • Biomay AG
  • Cedar Pollen Allergy - Drug Profiles
  • BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE

About ## percent of people who have food allergies are allergic to more than one food.

  • Allergy
  • Asthma
  • Pharmaceutical
  • Japan
  • Product Initiative
  • Cat Allergy - Drug Profiles
  • Allergen for Cat Allergy - Drug Profile

Cat allergy is an allergic reaction to one or more allergens produced by cats.

  • Allergy
  • Asthma
  • Chronic Disease
  • World
  • Product Initiative
  • VACCINE FOR HOUSE DUST MITE ALLERGY - DRUG PROFILE
  • House Dust Mite Allergy - Drug Profiles

HOUSE DUST MITE ALLERGY - PIPELINE BY STALLERGENES GREER PLC, H## 2019 House Dust Mite Allergy - Drug Profiles ALLERGAN FOR DUST MITE ALLERGY - DRUG PROFILE ALLERGEN FOR ALLERGIC ASTHMA AND HOUSE DUST MITE ALLERGY - DRUG PROFILE AM-## -

  • Allergy
  • Asthma
  • Pharmaceutical
  • World
  • Product Initiative
  • Cedar Pollen Allergy - Drug Profiles
  • BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE

BIOLOGIC FOR CEDAR POLLEN ALLERGY - DRUG PROFILE OMALIZUMAB - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description omalizumab F.

  • Allergy
  • Asthma
  • Pharmaceutical
  • Japan
  • Product Initiative
  • VACCINE FOR HOUSE DUST MITE ALLERGY - DRUG PROFILE
  • House Dust Mite Allergy - Drug Profiles

" House dust mite allergy is one of the most common allergies, impacting the quality of life for patients across ages and geographies.

  • Allergy
  • Asthma
  • Pharmaceutical
  • World
  • Product Initiative
  • Grass Pollen Allergy - Drug Profiles
  • Vaccine for Grass Pollen Allergy - Drug Profile

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Allergy
  • Asthma
  • Biotechnology
  • Medical Biotechnology
  • Product Initiative
  • ALLERGEN FOR ALLERGIC RHINITIS, ALLERGIC RHINO-CONJUNCTIVITIS AND BIRCH POLLEN ALLERGY - DRUG PROFILE
  • ALLERGEN FOR ALLERGIC RHINITIS AND RHINOCONJUNCTIVITIS - DRUG PROFILE

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy
  • Allergy Drug
  • Asthma
  • Ophthalmic Solution
  • Product Initiative
  • 1.2 Types of Allergy
  • Types of Allergies

Drug Allergy- The allergy from medicines, drugs is the most common form of allergy.

  • Allergy
  • Asthma
  • Respiratory Disease
  • World
  • Merck & Co., Inc.
  • 2.5 Types of Allergy by Allergens
  • Types of Allergy

The hypersensitivity of the body to sun rays causes sun allergy. ##. ## Types of Allergy by Allergens Drug Allergy-The allergy from medicines, drugs is the most common form of allergy.

  • Allergy
  • Asthma
  • World
  • Market Size
  • Allergy Therapeutics plc
  • headache, nasopharyngitis, bronchitis, sinusitis, fatigue and asthma.

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Allergy
  • Antifungal
  • Asthma
  • Digestive System Disorder
  • Therapy
  • trials that will further assess treatment of subsequent asthma attacks in mepolizumab-naive as well as previously-treated patients.

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Allergy
  • Antifungal
  • Asthma
  • Digestive System Disorder
  • United States
  • ALLERGEN FOR ALLERGIC RHINITIS, ALLERGIC RHINO-CONJUNCTIVITIS AND BIRCH POLLEN ALLERGY - DRUG PROFILE
  • Allergen for Allergic Rhinitis, Allergic Rhino-Conjunctivitis and Birch Pollen Allergy

The drug candidate activates allergen-specific T-helper type ## (Th##) cellular responses with the production of interferons by antigen presenting cells (APC), natural killer cells (NK), and T cells.

  • Allergy
  • Allergy Drug
  • Asthma
  • Eye Disease
  • Ophthalmic Solution
  • SUMMARIZES THE KEY PROJECTED PATENT EXPIRY DATES FOR PEANUT ALLERGY ACROSS THE 8MM.
  • KEY PROJECTED LAUNCH DATES FOR PEANUT ALLERGY, 2017-2027

WORLD ALLERGY ORGANIZATION JOURNAL, ##(##), PP. ##-##.

  • Allergy
  • Asthma
  • World
  • Forecast
  • Aimmune Therapeutics, Inc.
  • LATEST CLINICAL TRIALS NEWS ON PEANUT ALLERGY

" Although this is still in the experimental stages, we' re delivering on the hope of testing a drug that won' t be for one food allergy but for many, and for other allergic diseases, too. "

  • Allergy
  • Asthma
  • Therapy
  • World
  • Product Initiative
  • Major Companies

Stanford' s allergy clinics specialize in a range of allergic and immunological conditions, including asthma, eczema, food allergies, drug allergies and chronic urticaria (hives).

  • Allergy
  • Asthma
  • Chronic Disease
  • United States
  • Forecast
  • TRIALS THAT WILL FURTHER ASSESS TREATMENT OF SUBSEQUENT ASTHMA ATTACKS IN MEPOLIZUMAB-NAIVE AS WELL AS PREVIOUSLY-TREATED PATIENTS.

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Allergy
  • Asthma
  • Targeted Therapy
  • United States
  • Product Initiative

In July 2011, Oxagen Limited announced publication of data from a Phase IIa clinical trial of its development drug OC## in the journal Clinical & Experimental Allergy.

  • Allergy
  • Asthma
  • Clinical Trial
  • Respiratory Disease
  • Therapy
  • 2.1 RELATED REPORTS
  • MM, Probable Diagnosed Prevalent Cases of Peanut Allergy, All Ages, Both Sexes, N, 2017 and 2027

Peanut Allergy: Global Drug Forecast and Market Analysis to 2027, GDHC##PIDR GlobalData (2016).

  • Allergy
  • Asthma
  • Epidemiology
  • United States
  • Forecast
  • Feb 12, 2018: ASIT Biotech 2017 Annual Results: Ongoing ASIT+ Products Development in Respiratory and Food Allergies

ASIT biotech also received a & euro## million non-diluting financing from the Walloon Region for a very promising food allergy drug development program with the objective to select, by the end of this year, at least one product candidate with an optimal immunogenicity.

  • Allergy
  • Asthma
  • Belgium
  • Product Initiative
  • ASIT Biotech
  • ACT-774312 - DRUG PROFILE

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Allergy
  • Asthma
  • Dermatological Condition
  • Respiratory Disease
  • Therapy
  • HEADACHE, NASOPHARYNGITIS, BRONCHITIS, SINUSITIS, FATIGUE AND ASTHMA.

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Allergy
  • Asthma
  • Therapy
  • United States
  • Product Initiative